| Date | Title | Description |
| 19.06.2026 | Replicate Bioscience Awarded Grant to Advance srRNA Vaccine Candidates for Tuberculosis | Company receives grant from the Gates Foundation to develop srRNA vaccine candidates for tuberculosis, subject to humanitarian licensing terms
SAN DIEGO, June 19, 2026 /PRNewswire/ -- Replicate Bioscience, a clinical-stage company pioneerin... |
| 08.01.2026 | Replicate Bioscience Awarded Grants to Develop New srRNA Vaccines for HIV and Malaria | Company to receive approximately $7 million in funding from the Gates Foundation to use its srRNA platform to develop malaria and HIV candidates to address two of the world's most persistent public health burdens, subject to humanitarian li... |
| 08.01.2026 | Replicate Bioscience Awarded Grants to Develop New srRNA Vaccines for HIV and Malaria | Company to receive approximately $7 million in funding from the Gates Foundation to use its srRNA platform to develop malaria and HIV candidates to address two of the world's most persistent public health burdens, subject to humanitarian li... |
| 16.12.2025 | Replicate Bioscience Appoints Kathy Fernando, Ph.D., as Chief Business Officer | Senior biopharma executive with nearly 20 years of strategy, operational and business development experience will help lead Replicate's corporate strategy, partnerships and next chapter of growth
SAN DIEGO, Dec. 16, 2025 /PRNewswire/ -- Rep... |
| 04.12.2025 | Replicate Bioscience and Instituto Butantan Enter Collaborative Agreement to Develop and Commercialize Replicate’s Self-Replicating RNA (srRNA) Rabies Vaccine in Latin America | Under the agreement, Instituto Butantan will conduct registrational clinical trials of Replicate’s novel srRNA rabies vaccine for post-exposure and pre-exposure prophylaxis
Replicate to provide GMP material for clinical trials and transfer ... |
| 04.12.2025 | Replicate Bioscience and Instituto Butantan Enter Collaborative Agreement to Develop and Commercialize Replicate’s Self-Replicating RNA (srRNA) Rabies Vaccine in Latin America | Under the agreement, Instituto Butantan will conduct registrational clinical trials of Replicate’s novel srRNA rabies vaccine for post-exposure and pre-exposure prophylaxis
Replicate to provide GMP material for clinical trials and transfer ... |
| 24.09.2025 | Replicate Bioscience Announces Publication of Promising New Phase 1 Durability Data for Its srRNA Vaccine Candidate RBI-4000 | Eight month follow-up data published in Communications Medicine, a Nature portfolio journal
Full clinical dataset supports further development of RBI-4000 as a next generation vaccine approach for rabies, an ongoing global public health con... |
| 28.08.2025 | Replicate Bioscience Announces Partnership with Novo Nordisk to Unlock Self-Replicating RNA Therapies for Obesity and Diabetes | Partnership leverages Replicate's proprietary srRNA technology to create novel, scalable therapies for obesity, type 2 diabetes and other cardiometabolic diseases
Replicate will receive research funding and could potentially receive up to a... |
| 07.02.2025 | Replicate Bioscience Announces Publication of First-in-Human Data for Its Optimized srRNA Rabies Vaccine in Nature Communications | Results provide clinical demonstration of best-in-class immunogenicity achieved with an RNA-based platform and good tolerability
RBI-4000's potential to offer a meaningful improvement over existing vaccines for rabies, an ongoing global pub... |
| 21.08.2024 | Replicate Bioscience to Participate in Upcoming Investor and Scientific Conferences | SAN DIEGO, Aug. 21, 2024 /PRNewswire/ -- Replicate Bioscience, a clinical-stage company pioneering novel self-replicating RNA (srRNA) technology for applications across infectious disease, immunology, immuno-oncology and beyond, will be par... |
| 11.05.2024 | Replicate Bioscience Presents Positive Data from Phase 1 Trial and Preclinical Data with Novel Self-Replicating RNA at the 2024 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting | Positive data from Phase 1 trial of RBI-4000 vaccine achieve WHO-established surrogate of protection across all dose cohorts
Vector improvements demonstrate broad potential of Replicate’s srRNA for expanded indications in complex infectious... |
| 22.04.2024 | Replicate Bioscience Announces Oral Presentations at the 2024 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting | SAN DIEGO, April 22, 2024 /PRNewswire/ -- Replicate Bioscience, a clinical-stage company pioneering novel self-replicating RNA (srRNA) technology for use in infectious disease, oncology, autoimmune disease, and more, today announced accepta... |
| 01.03.2024 | Replicate Bioscience to Participate in Upcoming Investor and Scientific Conferences | SAN DIEGO, March 1, 2024 (PRNewswire) -- Replicate Bioscience, a clinical-stage company pioneering novel self-replicating RNA (srRNA) technology to expand applications of RNA vaccines and other treatments, will be participating in the follo... |
| 14.02.2024 | Replicate Bioscience Announces Positive Initial Clinical Results for its Next Generation srRNA Technology | Replicate's srRNA vaccine elicited a protective immune response that met the WHO threshold for protection at unparalleled low doses
Threshold for protection achieved with just a single dose of vaccine
RBI-4000 well-tolerated at all doses te... |
| 14.02.2024 | Replicate Bioscience Announces Positive Initial Clinical Results for its Next Generation srRNA Technology | Replicate's srRNA vaccine elicited a protective immune response that met the WHO threshold for protection at unparalleled low doses
Threshold for protection achieved with just a single dose of vaccine
RBI-4000 well-tolerated at all doses te... |
| 12.09.2023 | Replicate Bioscience Initiates a Phase 1 Trial of its Next-Generation srRNA Vaccine | SAN DIEGO, Sept. 12, 2023 /PRNewswire/ -- Replicate Bioscience, a clinical-stage company pioneering its novel self-replicating RNA (srRNA) technology to overcome the limitations of current mRNA modalities and expand use of RNA treatments to... |
| 10.07.2023 | Replicate Bioscience Appoints Rachael Lester as Chief Business Officer | Biopharma executive with more than 20 years of global corporate, business development, and commercial strategy experience to join Replicate leadership team
SAN DIEGO, Calif., July 10, 2023 – Replicate Bioscience, a company pioneering novel... |
| 10.07.2023 | Replicate Bioscience Appoints Rachael Lester as Chief Business Officer | Biopharma executive with more than 20 years of global corporate, business development, and commercial strategy experience to join Replicate leadership team |
| 19.04.2023 | Replicate Bioscience Presents Preclinical srRNA Data at the American Association for Cancer Research Annual Meeting 2023 | Preclinical studies provide proof-of-concept for Replicate's novel srRNA platform and programs
RBI-1000, Replicate's precision immuno-oncology program in development as an off-the-shelf treatment, induced robust immunity to multiple acquir... |
| 14.03.2023 | Replicate Bioscience Shares New Preclinical srRNA Data at American Association for Cancer Research Annual Meeting 2023 | Poster presentations provide data on Replicate's lead immuno-oncology candidate, RBI-1000, in targeting acquired resistance mutations and on another proof-of-concept study demonstrating the potential of Replicate's novel srRNA technology fo... |
| 12.10.2022 | Ascidian Therapeutics Launches to Rewrite RNA | ATP incubated and built Ascidian with $50 million in Series A funding
Pioneering RNA exon editing platform expands therapeutic possibilities to treat diseases not addressed by today’s gene editing technologies
Lead program targeting ABCA4... |
| 26.07.2022 | Precision NanoSystems and Replicate Bioscience in Licensing Deal to Scale Up Genomic Medicines | Companies aim to support development of up to 15 new genomic medicine products
Replicate’s commercial licensing of lipid nanoparticle technology from Precision NanoSystems at foundation of deal
SAN DIEGO, Calif., and Vancouver, British Co... |
| 26.07.2022 | Precision NanoSystems and Replicate Bioscience in Licensing Deal to Scale Up Genomic Medicines | Companies aim to support development of up to 15 new genomic medicine products |
| 12.07.2022 | Replicate Bioscience Expands Leadership Team, Appointing Zelanna Goldberg, M.D., as Chief Medical Officer and Mohit Trikha, Ph.D., to Board of Directors | SAN DIEGO, Calif., July 12, 2022/PRNewswire/ -- Replicate Bioscience, a company pioneering self-replicating RNA (srRNA) therapies for use against cancers, immune and inflammatory disorders, and other diseases, announced today that Zelanna G... |
| 09.06.2022 | Curia and Replicate Bioscience Enter Strategic Collaboration to Create Groundbreaking Development Platform for Self-Replicating RNA (srRNA) | ALBANY, N.Y.--(BUSINESS WIRE)--Curia, formerly AMRI, a leading contract research, development and manufacturing organization, and Replicate Bioscience, a company pioneering ways to prevent drug resistance in cancer and to treat autoimmune a... |
| 08.09.2021 | ATP Announces $40 Million in Series A Funding for srRNA Therapeutics Trailblazer Replicate Bioscience | NEW YORK and SAN DIEGO, Sept. 8, 2021 /PRNewswire/ -- ATP, a leader in life sciences venture capital, today announced the launch of Replicate Bioscience, a company pioneering ways to prevent drug resistance in cancer, and treat autoimmune a... |
| 08.09.2021 | ATP Announces $40 Million in Series A Funding for srRNA Therapeutics Trailblazer Replicate Bioscience | NEW YORK and SAN DIEGO, Calif., September 8, 2021/PR NEWSWIRE/ – ATP, a leader in life sciences venture capital, today announced the launch of Replicate Bioscience, a company pioneering ways to prevent drug resistance in cancer, and treat a... |
| 08.09.2021 | ATP Announces $40 Million in Series A Funding for srRNA Therapeutics Trailblazer Replicate Bioscience | NEW YORK and SAN DIEGO, Calif., September 8, 2021/PR NEWSWIRE/ – ATP, a leader in life sciences venture capital, today announced the launch of Replicate Bioscience, a company pioneering ways to prevent drug resistance in cancer, and treat a... |
| 08.09.2021 | Replicate Bioscience Lands $40M in Series A |
SAN DIEGO, CA, Replicate Bioscience has raised $40 million in committed Series A.
>> Click here for more funding data on Replicate Bioscience
>> To export Replicate Bioscience funding data to PDF and Excel, click here
ATP... |
| 08.09.2021 |
Replicate Biosciences Gets $40M
| San Diego-based Replicate Bioscience, which is looking to use self-replicating RNA (srRNA) to treat cancer, autoimmune, inflammatory disorders and other diseases, has raised $40M in its Series A funding. The funding was led by life sciences... |
| 08.09.2021 | ATP Announces $40 Million in Series A Funding for srRNA Therapeutics Trailblazer Replicate Bioscience | |
